86 Morris Avenue
At Celgene Corporation, we’re committed to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first. As a global leader in biotechnology and CAR T cell therapy, Celgene is a place where employees can make a real impact on the lives of patients with unmet medical needs in cancer and inflammatory diseases.
As we rapidly advance our next wave of innovative medicines, we announce the creation of a new global Clinical Development Organization to accelerate and optimize clinical development across our entire mid- to late-stage portfolio. Our commitments in this area will further establish the function as a center of excellence and enhance our strategic leadership in discovery, development and commercialization.
Recognized by Forbes in 2018 as a Top 10 World’s Best Employer and by Business Insider as the #3 Most Reputable Pharma Company in the World, Celgene offers a unique work environment where you can help build the business, while building your career in ways you may not have thought possible. We’re looking for innovative self-starters who want to improve the lives of patients worldwide. For more information, visit https://www.celgene.com/careers/.
CAR T cell therapy is a groundbreaking immunotherapy treatment that leverages a patient’s own immune system in fighting their cancer. Celgene is looking for dedicated people to join our team in this exciting area of cancer treatment.
974 articles with Celgene
A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
While the primary endpoint of disease-free survival was not met, Celgene said overall survival, which was a secondary endpoint, was improved by the combination treatment.
Humira generated nearly $20 billion in revenue for the Illinois-based company. Celgene's Revlimid earned about half-as-much in 2018.
Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer
TECENTRIQ® in Combination with ABRAXANE® receives accelerated approval for people with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
The next couple of weeks look to be busy for the FDA, with a string of target action dates scheduled. This week marks three scheduled approvals, two for extra indications for already-approved biologics, and the third for a combination treatment for glaucoma. Here’s a look.
On Friday, March 8, Bristol-Myers Squibb executives met with sell-side analysts to sell its $74 billion Celgene buyout.
Bristol-Myers Squibb and Celgene Corporation are strongly urging shareholders to submit their proxy votes as quickly as possible whether they plan to attend the April 12, 2019 Special Meeting or not. The meeting is when the official vote on whether Bristol-Myers Squibb will buy Celgene will take ...
Bristol-Myers Squibb announced its bid to acquire Celgene on January 3, 2019. However, the deal hit a snag. Bristol-Myers Squibb is now fighting back, making efforts to sell the deal to its shareholders.
U.S. Food & Drug Administration sets Prescription Drug User Fee Act action date for Sept. 3, 2019
The U.S. Food and Drug Administration (FDA) accepted Celgene’s New Drug Application (NDA) for fedratinib for myelofibrosis. It also granted it a Priority Review, with a target action date of September 3, 2019.
Adagene, Inc., an innovative antibody discovery and engineering company, announced a multi-target platform evaluation with Celgene Corporation.
According to a recent BioSpace survey, 70% of life science employers indicated their company anticipates an increase in the number of open positions during 2019. So if you are on the job hunt, keep your eye out for new positions posted throughout the year!
Bristol-Myers Squibb Company issued the following statement in response to a letter from Starboard Value
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
Shares of Bristol-Myers Squibb took a hit Wednesday after two large stakeholders in the company objected to the pending acquisition of Celgene. Wellington and Starboard Value have both publicly voiced opposition to the deal.
Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia
U.S. FDA grants Priority Review for REVLIMID® (lenalidomide) in combination with rituximab (R²) for previously treated follicular and marginal zone lymphoma
Bristol-Myers Squibb Announces Filing of Definitive Proxy Statement in Connection with Proposed Merger with Celgene
Schedules April 12, 2019 Special Meeting of Stockholders to Vote on Transaction
- Amends Registration Statement on Form S-4 with SEC - Remains on Track to Hold Special Meetings of Stockholders on April 12, 2019 - Updated Investor Presentation Highlights Strong Strategic and Financial Merits of Transaction
Lyfebulb and Celgene Announce Call for Innovation Challenge Applications to Address Unmet Needs in Multiple Sclerosis
Applications to be accepted through Friday, April 12 at 11:59 p.m. EDT
Paris-based Sanofi announced positive results from its pivotal Phase III trial of isatuximab in patients with relapsed/refractory multiple myeloma.